Sustained neurobehavioral effects of exposure to ssri antidepressants during development: Molecular to clinical evidence

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 672-677

  Oberlander, T F ^a,b   Gingrich, J A ^c   Ansorge, M S ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; CHILD BEHAVIOR; CHILD DEVELOPMENT; COGNITION; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG BRAIN LEVEL; EYE MOVEMENT; FETUS DEVELOPMENT; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOREACTIVITY; MATERNAL STRESS; MENTAL DISEASE; MOOD DISORDER; NERVE CELL DIFFERENTIATION; NONHUMAN; PERINATAL DRUG EXPOSURE; PLACENTA; PREGNANCY; PRENATAL DEVELOPMENT; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE; PRENATAL PERIOD; PRENATAL STRESS; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SPATIAL MEMORY; STRESS; SYNAPTIC TRANSMISSION; THIRD TRIMESTER PREGNANCY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHILD; CHILD BEHAVIOR; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DEPRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFANT; INFANT BEHAVIOR; INFANT, NEWBORN; MODELS, ANIMAL; NERVOUS SYSTEM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TRANSLATIONAL RESEARCH;

EID: 70450152340     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.201     Document Type: Review

References (30)

1. Oberlander, T.F., Warburton, W., Misri, S., Aghajanian, J. & Hertzman, C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 63, 898-906 (2006).
2. Talge, N.M., Neal, C. & Glover, V.; Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-term efects on child neurodevelopment: how and why? J. Child Psychol. Psychiatry 48, 245-261 (2007).
3. Gentile, S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 19, 623-633 (2005).
4. Kim, J. et al. Stereoselective disposition of fuoxetine and norfuoxetine during pregnancy and breast-feeding. Br. J. Clin. Pharmacol. 61, 155-163 (2006).
5. Gaspar, P., Cases, O. & Maroteaux, L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4, 1002-1012 (2003).
6. Ansorge, M.S., Hen, R. & Gingrich, J.A. Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 7, 8-17 (2007).
7. Hayashi, A., Nagaoka, M., Yamada, K., Ichitani, Y., Miake, Y. & Okado, N. Maternal stress induces synaptic loss and developmental disabilities of ofspring. Int. J. Dev. Neurosci. 16, 209-216 (1998).
8. Peters, D.A. Maternal stress increases fetal brain and neonatal cerebral cortex 5-hydroxytryptamine synthesis in rats: a possible mechanism by which stress infuences brain development. Pharmacol. Biochem. Behav. 35, 943-947 (1990).
9. Lira, A. et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-defcient mice. Biol. Psychiatry 54, 960-971 (2003).
10. Ansorge, M.S., Morelli, E. & Gingrich, J.A. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J. Neurosci. 28, 199-207 (2008).
11. Ansorge, M.S., Zhou, M., Lira, A., Hen, R. & Gingrich, J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306, 879-881 (2004).
12. Popa, D., Léna, C., Alexandre, C. & Adrien, J. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J. Neurosci. 28, 3546-3554 (2008).
13. Vogel, G., Neill, D., Hagler, M. & Kors, D. A new animal model of endogenous depression: a summary of present fndings. Neurosci. Biobehav. Rev. 14, 85-91 (1990). (Pubitemid 20115617)
14. Kinney, G.G., Vogel, G.W. & Feng, P. Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Brain Res. 756, 68-75 (1997).
15. Maciag, D. et al. Neonatal antidepressant exposure has lasting efects on behavior and serotonin circuitry. Neuropsychopharmacology 31, 47-57 (2006).
16. Morrison, J.L., Chien, C., Gruber, N., Rurak, D. & Riggs, W. Fetal behavioural state changes following maternal fuoxetine infusion in sheep. Brain Res. Dev. Brain Res. 131, 47-56 (2001).
17. Moses-Kolko, E.L. et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293, 2372-2383 (2005).
18. Salisbury, A.L. & Dipietro, J. Prenatal serotonin reuptake inhibitor exposure: fetal and infant outcomes. Dev. Psychobiol. 48, 624 (2006).
19. Zeskind, P.S. & Stephens, L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113, 368-375 (2004).
20. Oberlander, T.F. et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr. Res. 51, 443-453 (2002).
21. Oberlander, T.F., Grunau, R.E., Fitzgerald, C., Papsdorf, M., Rurak, D. & Riggs, W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115, 411-425 (2005).
22. Laine, K., Heikkinen, T., Ekblad, U. & Kero, P. Efects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60, 720-726 (2003).
23. Pawluski, J.L., Galea, L.A.M., Brain, U., Papsdorf, M. & Oberlander, T.F. neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 124, e662-e670 (2009).
24. Hilli, J. et al. MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur. Neuropsychopharmacol. 19, 363-370 (2009).
25. Davidson, S. et al. Efect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr. Res. 65, 236-241 (2009).
26. Oberlander, T.F. et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum. Dev. 84, 689-697 (2008).
27. Casper, R.C. et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142, 402-408 (2003).
28. Nulman, I. et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336, 258-262 (1997).
29. Oberlander, T.F., Reebye, P., Misri, S., Papsdorf, M., Kim, J. & Grunau, R.E. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 161, 22-29 (2007).
30. Oberlander, T.F., Bonaguro, R.J., Misri, S., Papsdorf, M., Ross, C.J. & Simpson, E.M. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol. Psychiatry 13, 65-73 (2008).